Evidence map›Paper›PMID 40361171›Full record

ArticleBMC surgery2025

Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol.

Luís Filipe Abreu de Carvalho, Filip Gryspeerdt, Wim Ceelen, Karen Geboes, Suzane Ribeiro, Anne Hoorens, Nele Vandenbussche, Kathleen B M Claes, Clarisse Lecluyse, Aliaksandr Anisau and 9 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05298722 (Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05298722 narecruitingnot on this map

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy

TypeinterventionalSponsorUniversity Hospital, GhentRan2022 to 2028Enrolled45ConditionsPancreatic CancerArmsImaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Luís Filipe Abreu de CarvalhoDepartment of HPB surgery and liver transplantation, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, 9000, Belgium. Luis.AbreudeCarvalho@UZGent.be.
Filip GryspeerdtDepartment of HPB surgery and liver transplantation, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, 9000, Belgium.
Wim CeelenDepartment of Gastrointestinal surgery, Ghent University Hospital, Ghent, Belgium.
Karen GeboesDepartment of Gastroenterology, Division of Digestive Oncology, Ghent University Hospital, Ghent, Belgium.
Suzane RibeiroDepartment of Gastroenterology, Division of Endoscopy and Digestive Oncology, Ghent University Hospital, Ghent, Belgium.
Anne HoorensDepartment of Pathology, Ghent University Hospital, Ghent, Belgium.
Nele VandenbusscheCenter for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Kathleen B M ClaesCenter for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Clarisse LecluyseDepartment of Medical Imaging, Ghent University Hospital, Ghent, Belgium.
Aliaksandr AnisauDepartment of Medical Imaging, Ghent University Hospital, Ghent, Belgium.
Johan Van OngevalDepartment of Gastroenterology, Division of Digestive Oncology, Ghent Sint-Lucas hospital, Ghent, Belgium.
Willem LybaertDepartment of Gastroenterology, Division of Digestive Oncology, VITAZ hospital, Sint-Niklaas, Belgium.
Lars TriestDepartment of Gastroenterology, Division of Digestive Oncology, Sint-Blasius hospital, Dendermonde, Belgium.
Andrew VervaeckeDepartment of Gastroenterology, Zeno Hospital, Knokke-Heist and Blankenberge, Knokke-Heist, Belgium.
Steven SasDepartment of Gastroenterology, Division of Digestive Oncology, Jan Palfijn hospital, Ghent, Belgium.
Barbara ClaerhoutDepartment of Gastroenterology, Division of Digestive Oncology, Eeklo Hospital AZ ALMA, Eeklo, Belgium.
Carolien BeylsDepartment of Gastroenterology, Division of Digestive Oncology, Oudenaarde hospital, Oudenaarde, Belgium.
Mark SieDepartment of Medical Oncology, Division of Digestive Oncology, Zorgsaam hospital, Terneuzen, The Netherlands.
Frederik BerrevoetDepartment of HPB surgery and liver transplantation, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, 9000, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy is used in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) to increase resection rate and improve cancer outcome. However, there is a need for better prediction of resectability. The aim of this prospective, single arm study is to improve prediction of surgical resection by using radiomics and liquid biopsy.

methodsIn this multicentric trial, 45 patients with BR or LA PADC will undergo neoadjuvant chemotherapy with FOLFIRINOX. An intention to treat analysis will be performed. The primary endpoint is the accuracy of the prediction of surgical resection. Secondary endpoints are overall survival and disease-free survival from the date of diagnosis, R0 and R1 resection rates, histopathological response, postoperative complications, patient reported outcomes with quality of life and health economic analysis. Translational research with multi-omics and radiomics based on computed tomography and magnetic resonance imaging aims to identify factors predictive of surgical resectability and survival. The primary hypothesis is that these strategies can increase the accuracy of predicting surgical resection. DISCUSSION: Improved prediction of resectability is necessary in BR and LA PDAC. We aim to investigate whether a combination of clinical, radiological, and multi-omics profiling in liquid biopsies can successfully predict resectability and thus optimize the therapeutic decision tree.

trial registrationClinicalTrials.gov Identifier: NCT05298722. Date of registration: March 28, 2022.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalPancreatectomyPancreatic NeoplasmsFemaleFluorouracilHumansIrinotecanLeucovorinMaleMulticenter Studies as TopicNeoadjuvant TherapyOxaliplatinProspective StudiesFluorouracilfolfirinoxIrinotecanLeucovorinOxaliplatinBorderline resectable pancreatic cancerFOLFIRINOXLiquid biopsyLocally advanced pancreatic cancerMulti-omicsNeoadjuvant chemotherapyPancreatic cancerPrecision oncology

Identifiers

PMID40361171
PMCPMC12070518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.